GHRL and neoplasm: Actually, results from our group led to the identification of previously unrecognized aberrant splicing variants from somatostatin and ghrelin systems (SST5TMD4/5 and In1-ghrelin) and demonstrated that these variants are overexpressed in tumors and can contribute to their oncogenesis, increasing aggressiveness and malignant features in different tumor types, including PitNETs [17,18,19,20,21,22,31,39,40].